Amvuttra (Vutrisiran) for amyloidosis

Overview
Amvuttra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Amvuttra is also referred to by its drug name, vutrisiran.

Amvuttra is a member of a class of drugs called small interfering ribonucleic acids (siRNA). Amvuttra is believed to work by interfering with the creation of amyloid proteins in cells.

How do I take it?
Prescribing information states that Amvuttra is given as a subcutaneous (under the skin) injection by a health care professional. Amvuttra is administered in a health clinic or doctor’s office once every three months.

Side effects
The FDA-approved label for Amvuttra lists common side effects as pain in extremities, joint pain, difficulty breathing.

Vitamin A deficiency is listed as a potential serious side effect for Amvuttra.

For more details about this treatment, visit:

Amvuttra — Alnylam
https://www.amvuttra.com